Nyxoah’s (NYXH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a research report released on Friday, MarketBeat.com reports. The firm currently has a $17.00 price target on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Nyxoah in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $17.00.

Nyxoah Trading Up 1.5 %

NASDAQ:NYXH opened at $8.00 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $199.52 million, a price-to-earnings ratio of -4.28 and a beta of 1.35. The firm has a fifty day simple moving average of $8.86 and a two-hundred day simple moving average of $8.53. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. Kovack Advisors Inc. acquired a new stake in shares of Nyxoah S.A. (NASDAQ:NYXH) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $96,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.